Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|2|180-188

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.2, 2016-01, pp. : 180-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of standard and novel therapies in Crohn’s disease

By Rulyak S.J.   Lichtenstein G.R.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 7, 2000-07 ,pp. : 1021-1033

Informa Healthcare

Access to resources Recommend Favorite

Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization

By Tilg Herbert  

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 6, 2007-06 ,pp. : 853-856

Informa Healthcare

Access to resources Recommend Favorite

Probiotics in the Management of Crohn's disease and Ulcerative Colitis

By  

Current Pharmaceutical Design, Vol. 20, Iss. 28, 2014-08 ,pp. : 4556-4560

Bentham Science Publishers

Access to resources Recommend Favorite

Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease

By Fiedler T.   Büning C.   Reuter W.   Pitre G.   Gentz E.   Schmidt HH.   Büttner J.   Ockenga J.   Gerloff T.   Meisel C.   Lochs H.   Roots I.   Köpke K.   Johne A.  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 10, 2007-10 ,pp. : 917-925

Springer Publishing Company

Access to resources Recommend Favorite

Economic Implications of Biological Therapies for Crohn’s Disease: Review of Infliximab

By Bodger Keith  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite